Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Price History
|
Ratios
|
Insiders
Bullboard - Stock Discussion Forum
Crescita Therapeutics Inc
T.CTX
Alternate Symbol(s):
CRRTF
Healthcare
Drug Manufacturers - Specialty & Generic
Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally. It operates through three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The company owns proprietary drug delivery platforms, which include Multiplexed Molecular Penetration...
Enhancers and DuraPee that supports the development of patented formulations to facilitate the delivery of active ingredients into or through the skin. The company’s prescription products include Pliaglis, a topical local anesthetic cream that provides dermal analgesia on intact skin prior to superficial dermatological procedures. Its non-prescription portfolio offers dermocosmetic products, such as face creams, cleansers, exfoliants, masks, serums, and suncare to treat mild acne, aging, dehydration, pigmentation, sensitivity, and rosacea under the Laboratoire Dr Renaud and Aquafolia brands; and m...
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Bullboard (TSX:CTX)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
Next
(1181)
•••
lscfa
X
Post by
lscfa
on Jul 19, 2024 8:57am
5 yr contract
Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house R&D and
...more
(1181)
•••
lscfa
X
Post by
lscfa
on Mar 15, 2024 12:37am
Q4 on sedar
Skincare biz growing. Looking for new customers for their contract manufacturing biz where the plant has a capacity of $25 mil/yr. Skincare
...more
(1181)
•••
lscfa
X
Comment by
lscfa
on Mar 15, 2024 12:32am
RE:NCAV = $0.637/share
Cash/share = $0.47 and cash flow positive biz
(18)
•••
Stonksonlyup90
X
Post by
Stonksonlyup90
on Mar 13, 2024 8:40pm
NCAV = $0.637/share
After the release of financials this week I'm seeing NCAV at $0.637/share. Despite struggles in their manufacturing segment this does seem grossly undervalued here. What are the chances the
...more
(3)
•••
daydream1
X
Comment by
daydream1
on Nov 09, 2023 9:34am
RE:RE:RE:RE:Net-Net Stock - cheap stock
Management knew a while ago the Taro deal was done and dead. There was no proactive steps taken by them at all. This company is done, cash will only evaporates over time. The only outcome is for them
...more
(5)
•••
drewmumaw
X
Comment by
drewmumaw
on Nov 08, 2023 10:58am
RE:RE:RE:Net-Net Stock - cheap stock
So much for the down side being limited. Disastrous Q3 results released today.
(7)
•••
stef1234
X
Comment by
stef1234
on Oct 04, 2023 7:54pm
RE:RE:Net-Net Stock - cheap stock
I agree totally with your comments Drewmumaw. You nailed down the issue with this company. As Warren Buffet said it many times, we can't as a passive investor replace a management team
...more
(5)
•••
drewmumaw
X
Comment by
drewmumaw
on Sep 29, 2023 3:30pm
RE:Net-Net Stock - cheap stock
"...I believe the downside is very limited." Agreed. But the upside appears very limited too. Current management can’t seem to find a way to grow the business. Their compensation seems way
...more
(1181)
•••
lscfa
X
Comment by
lscfa
on Aug 27, 2023 2:40pm
RE:Net-Net Stock - cheap stock
working capital $0.75/sh
(7)
•••
stef1234
X
Post by
stef1234
on Aug 12, 2023 6:47pm
Net-Net Stock - cheap stock
I recently bought this company. Pretty cheap stock by any standard. Looks very similar to CPH, IBT and MPH pharma plays. Management has began the turnaround, so Revenue and Profit
...more
(431)
•••
prophetoffactz
X
Post by
prophetoffactz
on Dec 18, 2022 10:53am
New Interview: 'It's an exciting time at CTX right now'
(6)
•••
DrewJackson
X
Comment by
DrewJackson
on Aug 29, 2022 10:16am
RE:RE:RE:Ghost town here
Crescita needs a new CEO, in my opinion.
(18)
•••
Stonksonlyup90
X
Comment by
Stonksonlyup90
on Mar 24, 2022 2:10pm
RE:RE:Ghost town here
Tell that to the share price... EV at $0.80 is roughly $5.3M.. lumpy or not the TTM EBITDA is $1M (anticipated to grow with the large PO secured this past year). if we do, say $1M in
...more
(1181)
•••
lscfa
X
Comment by
lscfa
on Mar 24, 2022 12:04am
RE:Ghost town here
Co. has lumpy revenues due to 1-time upfront licensing fees so looking at a qtr is unwise. 12 month revenues little changed and profitability is weak.
(24)
•••
Eldoradosucks
X
Comment by
Eldoradosucks
on Mar 23, 2022 11:29pm
RE:Ghost town here
Let's hope this get higher. It's really undervalued
Prev
1
2
3
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
{{previousButtonTitle}}
{{nextButtonTitle}}
A daily snapshot of everything
from market open to close.
Podcasts